Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NASDAQ:AYTU NASDAQ:KZIA NASDAQ:NEUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$1.47+3.5%$1.96$1.33▼$12.60$6.32M-2.091.67 million shs41,965 shsAYTUAytu BioPharma$2.19-2.7%$2.33$1.65▼$3.07$23.50M0.2459,360 shs14,423 shsKZIANovogen$14.63-0.4%$12.54$4.86▼$17.40$24.14M2.17217,314 shs206,255 shsNEUPNeuphoria Therapeutics$4.49+3.0%$4.89$3.64▼$21.40$24.27M0.7250,446 shs32,878 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-5.96%-7.79%-27.92%-66.74%-88.22%AYTUAytu BioPharma-0.44%+7.69%+2.28%-17.34%+13.13%KZIANovogen+4.93%+6.68%+7.54%+101.23%+116.99%NEUPNeuphoria Therapeutics-1.80%+1.87%-20.44%-0.23%-27.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$1.47+3.5%$1.96$1.33▼$12.60$6.32M-2.091.67 million shs41,965 shsAYTUAytu BioPharma$2.19-2.7%$2.33$1.65▼$3.07$23.50M0.2459,360 shs14,423 shsKZIANovogen$14.63-0.4%$12.54$4.86▼$17.40$24.14M2.17217,314 shs206,255 shsNEUPNeuphoria Therapeutics$4.49+3.0%$4.89$3.64▼$21.40$24.27M0.7250,446 shs32,878 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-5.96%-7.79%-27.92%-66.74%-88.22%AYTUAytu BioPharma-0.44%+7.69%+2.28%-17.34%+13.13%KZIANovogen+4.93%+6.68%+7.54%+101.23%+116.99%NEUPNeuphoria Therapeutics-1.80%+1.87%-20.44%-0.23%-27.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 2.00Hold$31.002,008.84% UpsideAYTUAytu BioPharma 2.40Hold$9.83349.01% UpsideKZIANovogen 2.60Moderate Buy$23.7562.34% UpsideNEUPNeuphoria Therapeutics 2.00Hold$21.00367.71% UpsideCurrent Analyst Ratings BreakdownLatest ACXP, KZIA, AYTU, and NEUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026AYTUAytu BioPharma Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $14.506/11/2026KZIANovogen Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.006/1/2026NEUPNeuphoria Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026NEUPNeuphoria Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/11/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ACXPAcurx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.004/8/2026AYTUAytu BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$2.07 per shareN/AAYTUAytu BioPharma$66.38M0.35$0.37 per share5.99$2.11 per share1.04KZIANovogen$30K804.65N/AN/A($5.34) per share-2.74NEUPNeuphoria Therapeutics-$13.27K-1,829.23$0.16 per share28.49$10.11 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$7.97M-$4.05N/AN/AN/AN/A-153.92%-101.69%8/10/2026 (Estimated)AYTUAytu BioPharma-$13.56M-$4.58N/A8.76N/A-60.17%-69.93%-13.25%N/AKZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/A9/4/2026 (Estimated)NEUPNeuphoria Therapeutics-$370K-$11.06N/AN/AN/AN/A-76.93%-54.76%9/2/2026 (Estimated)Latest ACXP, KZIA, AYTU, and NEUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q3 2026NEUPNeuphoria Therapeutics-$0.56-$0.09+$0.47-$0.09N/AN/A5/13/2026Q3 2026AYTUAytu BioPharma-$0.4433-$0.53-$0.0867-$0.53$12.05 million$12.41 million5/12/2026Q1 2026ACXPAcurx Pharmaceuticals-$0.59-$0.62-$0.03-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A3.783.78AYTUAytu BioPharma0.271.121.00KZIANovogenN/A2.87N/ANEUPNeuphoria TherapeuticsN/A14.3114.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%AYTUAytu BioPharma33.49%KZIANovogen30.89%NEUPNeuphoria Therapeutics15.90%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%AYTUAytu BioPharma4.90%KZIANovogen1.00%NEUPNeuphoria Therapeutics1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals34.30 million3.43 millionNo DataAYTUAytu BioPharma16010.73 million10.21 millionNot OptionableKZIANovogen121.65 million1.64 millionNo DataNEUPNeuphoria TherapeuticsN/A5.41 million5.32 millionN/AACXP, KZIA, AYTU, and NEUP HeadlinesRecent News About These CompaniesShort Interest in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Increases By 88.0%June 15, 2026 | americanbankingnews.comHC Wainwright & Co. downgrades Neuphoria Therapeutics (NEUP)May 17, 2026 | msn.comNeuphoria Therapeutics (NEUP) price target increased by 38.22% to 13.77May 14, 2026 | msn.comHere's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationFebruary 19, 2026 | uk.finance.yahoo.comNeuphoria Therapeutics (NEUP) price target decreased by 32.33% to 9.96December 22, 2025 | msn.comLeading Advisory Firms Recommend Voting FOR Lynx1's Independent NomineesDecember 8, 2025 | marketwatch.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director NomineesDecember 8, 2025 | markets.businessinsider.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director NomineesDecember 8, 2025 | globenewswire.comHC Wainwright & Co. maintains Neuphoria Therapeutics (NEUP) buy recommendationDecember 5, 2025 | msn.comNeuphoria Therapeutics price target lowered to $7 from $21 at HC WainwrightDecember 5, 2025 | msn.comNeuphoria Therapeutics responds to Lynx1’s revised indication of interestDecember 4, 2025 | msn.comNeuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and PremiumDecember 4, 2025 | finance.yahoo.comNeuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and PremiumDecember 4, 2025 | globenewswire.comLynx1 Sends Open Letter to Fellow Neuphoria ShareholdersDecember 3, 2025 | finance.yahoo.comNeuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1December 1, 2025 | msn.comNeuphoria Therapeutics Inc. Responds to Allegations from Lynx1 Master Fund LP, Urges Stockholders to Support Its NomineesDecember 1, 2025 | quiverquant.comQNeuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 FictionsDecember 1, 2025 | globenewswire.comNeuphoria Therapeutics urges stockholders to vote for company nomineesNovember 24, 2025 | msn.comNeuphoria Therapeutics Inc. Sends Letter to StockholdersNovember 24, 2025 | globenewswire.comNeuphoria Therapeutics (NEUP) Price Target Decreased by 25.73% to 14.72November 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACXP, KZIA, AYTU, and NEUP Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$1.47 +0.05 (+3.52%) Closing price 04:00 PM EasternExtended Trading$1.46 0.00 (-0.34%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Aytu BioPharma NASDAQ:AYTU$2.19 -0.06 (-2.67%) Closing price 04:00 PM EasternExtended Trading$2.18 -0.01 (-0.46%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Novogen NASDAQ:KZIA$14.63 -0.06 (-0.41%) Closing price 04:00 PM EasternExtended Trading$14.72 +0.09 (+0.59%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Neuphoria Therapeutics NASDAQ:NEUP$4.49 +0.13 (+2.98%) Closing price 04:00 PM EasternExtended Trading$4.34 -0.15 (-3.23%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
